On October 3, 2025, Rocket Pharmaceuticals, Inc. withdrew its Biologics License Application (BLA) for the gene therapy RP-L102, which is aimed at treating Fanconi Anemia, due to strategic business decisions. This action follows earlier withdrawals in July 2025 of its Marketing Authorization Application in Europe and aims to focus resources on programs with clearer regulatory pathways.